Buy ARTH - Two Gifts for You Michael Murphy CFA
Sent: 9/20/2016 1:46:10 P.M. US Mountain Standard Time
Subj: Buy ARTH - Two Gifts for You
You opted-in to receive free stock and market updates when you subscribed to New World Investor. Easily unsubscribe by clicking the link at the very bottom of this newsletter.
Dear New World Investor:
My first gift: I want to be sure you know that Arch Therapeutics (ARTH) is the current recovery trade, and it is just under my buy limit. ARTH has a new, patented liquid that stops bleeding in seconds. It will be widely used in surgery, EMS situations, and on the battlefield. It is regulated as a device, not a drug, and therefore only needs one clinical trial for approval.
The company just finished a very successful clinical trial in Europe, and will apply for the CE mark by the end of the year. In 2017 they will complete a US trial and file for FDA approval.
What's really exciting about ARTH is that the US market alone for hemostats to stop bleeding is $5 billion. Arch's product is far superior to what's on the market now, yet the whole market capitalization of the company is only $80 million. The next drivers for the stock will be:
* * Signing a deal for European distribution, which should net them a milestone payment large enough to fund the FDA approval process
* * Publishing the European trial results in a peer-reviewed journal
* * Applying for the CE mark
* * Getting the CE mark
* * The US clinical trial
The company is run by an MD/MBA who used to run Putnam's healthcare fund. He's very financially sophisticated and owns a big block of the stock. At 60 cents a share, please check it out! My first target is $3.50, and I expect to see double-digits in a few years.
GLTA,
Michael Murphy CFA
Elevator Summary of Company http://www.archtherapeutics.blogspot.com/
